Fengyuan Zhongke

Anhui Fengyuan Zhongke Biopharmaceutical is a high-tech enterprise established through a strategic partnership between Anhui Fengyuan Group (BBCA Group) and the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS). The company serves as a major industrialization hub for biopharmaceutical innovations, specifically focusing on the large-scale production of recombinant protein vaccines and therapeutic biologics. Its most prominent achievement is the manufacturing and scale-up of the ZF2001 (Zifivax) recombinant protein COVID-19 vaccine, which was developed in collaboration with the Chinese Academy of Sciences. Located in Bengbu, Anhui, the company operates extensive GMP-compliant facilities equipped for high-volume biological fermentation and protein purification. Fengyuan Zhongke plays a critical role in translating academic biotechnology research into commercial-scale healthcare solutions, leveraging the parent group's deep expertise in fermentation technology.